| Identification | Back Directory | [Name]
ICRF-186 | [CAS]
24613-06-7 | [Synonyms]
ICRF-186 R- Dexrazoxane Dexrazoxane Impurity 9 (R)-Razoxane (Levrazoxane) (R)-4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione) 4,4'-[(R)-1-Methyl-1,2-ethanediyl]bis(2,6-piperazinedione) 2,6-Piperazinedione, 4,4'-[(1R)-1-methyl-1,2-ethanediyl]bis- (9CI) | [Molecular Formula]
C11H16N4O4 | [MDL Number]
MFCD00870253 | [MOL File]
24613-06-7.mol | [Molecular Weight]
268.27 |
| Chemical Properties | Back Directory | [Boiling point ]
531.5±50.0 °C(Predicted) | [density ]
1.333±0.06 g/cm3(Predicted) | [pka]
11.00±0.20(Predicted) | [InChI]
InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m1/s1 | [InChIKey]
BMKDZUISNHGIBY-SSDOTTSWSA-N | [SMILES]
[C@@H](N1CC(=O)NC(=O)C1)(C)CN1CC(=O)NC(=O)C1 |
| Hazard Information | Back Directory | [Uses]
(R)-Levrazoxane ((R)-ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases[1]. | [References]
[1] Hasinoff BB, et al. Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica. 1994 Oct;24(10):977-87. DOI:10.3109/00498259409043295 |
|
|